Preclinical studies have reveled that COX-2 inhibitors lower the proliferation of human lung cancer cells in combination with chemotherapy [14]; however, whether the combination of COX-2 inhibitors with radiotherapy has a better effect in NSCLC has not been investigated in clinical trials or laboratory studies. The gene discussed is PTGS2; the disease is lung carcinoma.